Invenra and Xcellon Biologics, a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody-drug conjugates (ADCs) and complex biologics, announced today a strategic collaboration to advance the development of multispecific ADCs.

According to a release, Invenra will leverage its proprietary B-Body Bispecific platform and T-Body Trispecific antibody platform to generate novel multispecific antibody formats, while Xcellon Biologics will provide bioconjugation, ADC development and manufacturing services to create and evaluate multispecific ADC candidates derived from these platforms.

“This collaboration represents a meaningful step toward realizing the therapeutic potential of bispecific and trispecific ADCs,” Invenra CEO Roland Green said in a statement. “Our B-Body and T-Body multispecific antibody discovery platforms are designed to unlock new biology and expand the reach of targeted therapies. Xcellon’s expertise in bioconjugation, ADC development and manufacturing makes them an ideal partner to help advance these innovative constructs toward the clinic.”

The timeline of the collaboration was not disclosed.

Xcellon Biologics is located in North Bethesda, Md.